First Financial Bank Trust Division boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,505 shares of the company’s stock after purchasing an additional 100 shares during the quarter. First Financial Bank Trust Division’s holdings in Eli Lilly and were worth $1,589,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in the business. Perennial Advisors LLC acquired a new stake in shares of Eli Lilly and during the 4th quarter worth approximately $31,000. DB Wealth Management Group LLC bought a new position in Eli Lilly and in the fourth quarter valued at approximately $34,000. Retirement Group LLC acquired a new stake in Eli Lilly and during the 4th quarter worth $33,000. Archer Investment Corp raised its position in shares of Eli Lilly and by 83.3% during the 4th quarter. Archer Investment Corp now owns 220 shares of the company’s stock valued at $37,000 after acquiring an additional 100 shares during the last quarter. Finally, Accel Wealth Management acquired a new position in shares of Eli Lilly and in the 4th quarter valued at $37,000. Institutional investors own 75.59% of the company’s stock.
Eli Lilly and stock traded up $1.07 during midday trading on Thursday, reaching $183.39. 14,324 shares of the company’s stock were exchanged, compared to its average volume of 4,374,581. The stock’s 50-day simple moving average is $195.68 and its 200 day simple moving average is $171.39. The firm has a market cap of $175.87 billion, a price-to-earnings ratio of 29.79, a P/E/G ratio of 1.57 and a beta of 0.37. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36. Eli Lilly and Company has a 52 week low of $129.21 and a 52 week high of $218.00.
A number of research firms recently commented on LLY. Mizuho upped their price objective on Eli Lilly and from $222.00 to $228.00 and gave the company a “buy” rating in a report on Monday, February 1st. Wolfe Research raised Eli Lilly and from a “peer perform” rating to an “outperform” rating and upped their price target for the company from $147.00 to $183.00 in a research note on Thursday, December 10th. Truist lifted their price objective on shares of Eli Lilly and from $200.00 to $215.00 in a research note on Monday, February 1st. Morgan Stanley boosted their price objective on shares of Eli Lilly and from $190.00 to $217.00 and gave the company an “overweight” rating in a report on Thursday, February 4th. Finally, Truist Securities lifted their price target on shares of Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, March 22nd. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $193.88.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction on Wednesday, January 13th. The shares were sold at an average price of $185.97, for a total transaction of $39,053,700.00. Following the completion of the transaction, the insider now directly owns 110,807,418 shares of the company’s stock, valued at $20,606,855,525.46. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 555,284 shares of company stock valued at $106,132,302 in the last ninety days. Insiders own 0.09% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Read More: How is an ETF different from a mutual fund?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.